Research Analysts Set Expectations for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities research analysts at Zacks Research upped their Q3 2026 earnings per share (EPS) estimates for Becton, Dickinson and Company in a research note issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $4.02 per share for the quarter, up from their previous estimate of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the company posted $3.42 EPS. Becton, Dickinson and Company’s quarterly revenue was up 6.9% on a year-over-year basis.

Several other research firms also recently weighed in on BDX. Evercore ISI lifted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Trading Up 1.3 %

Shares of BDX opened at $243.69 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a market capitalization of $70.67 billion, a price-to-earnings ratio of 41.02, a PEG ratio of 1.72 and a beta of 0.39. The company has a 50-day moving average of $227.70 and a 200 day moving average of $232.88. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $248.42.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were issued a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.71%. The ex-dividend date of this dividend was Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This trade represents a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock valued at $2,210,716 in the last 90 days. Insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares during the period. Nordea Investment Management AB increased its holdings in shares of Becton, Dickinson and Company by 31.0% in the fourth quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after purchasing an additional 673,568 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after purchasing an additional 460,440 shares during the last quarter. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $108,243,000. Finally, The Manufacturers Life Insurance Company boosted its position in Becton, Dickinson and Company by 62.2% in the third quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock valued at $266,974,000 after buying an additional 424,487 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.